| Publication number |
CLPUB00802 |
|---|
| Authors |
Harris E., Vareslija D., O'Hara J., Hill A., Young L. |
|---|
| Title |
Characterising an aromatase inhibitor-resistant breast cancer cell line. |
|---|
| Citation |
RCSIsmj 5:97-98(2012) |
|---|
| Web pages |
https://web.archive.org/web/20231003143829/http://www.rcsismj.com/wp-content/uploads/RCSIsmj-Vol5-Aromatase-Inhibitor-Resistant-Breast-Ca.pdf |
|---|
| Abstract |
Aromatase inhibitors (AIs) are a novel adjuvant endocrine treatment for
oestrogen receptor (ER)-positive breast cancer in postmenopausal women.
They inhibit the conversion of androgens to oestrogens. In the clinic, AIs
have been shown to be superior to tamoxifen (a selective ER modulator),
with improved tolerability and increased disease-free survival. However,
prolonged use of AIs can lead to acquired resistance characterised by
aberrant ER signalling and crosstalk with growth factor pathways. An AI-
resistant breast cancer cell line, Let-R, is currently being investigated
and demonstrates differential oestrogen regulation of target genes. In
resistance, classical genes such as pS2 become oestrogen-independent.
However, cyclinD1 remains oestrogen-regulated and appears to be modulated
through oestrogen signalling to c-jun N-terminal kinase (JNK) in addition
to the ER. This study aims to characterise the Let-R cell line created in
the lab and to optimise an ER-alpha knockdown in Let-R cells.
|
|---|
| Cell lines |
CVCL_W348; MCF-7aro Let-R |
|---|
